Cargando…
Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies
OBJECTIVE: This study investigated mobile health enabled surveillance in ototoxicity. METHOD: This was a longitudinal study of 32 participants receiving chemotherapy. Baseline and exit audiograms that included conventional and extended high frequency audiometry were recorded within the patient'...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834705/ https://www.ncbi.nlm.nih.gov/pubmed/35611593 http://dx.doi.org/10.1017/S0022215122001281 |
_version_ | 1784868519956971520 |
---|---|
author | Ehlert, K Heinze, B Graham, M A Swanepoel, D |
author_facet | Ehlert, K Heinze, B Graham, M A Swanepoel, D |
author_sort | Ehlert, K |
collection | PubMed |
description | OBJECTIVE: This study investigated mobile health enabled surveillance in ototoxicity. METHOD: This was a longitudinal study of 32 participants receiving chemotherapy. Baseline and exit audiograms that included conventional and extended high frequency audiometry were recorded within the patient's treatment venue using a validated mobile health audiometer. RESULTS: Average hearing thresholds at baseline were within the normal range (81.2 per cent left; 93.8 per cent right), reducing at exit testing (71.9 per cent left; 78.1 per cent right). Half of participants presented with a threshold shift according to ototoxicity monitoring criteria. The frequencies affected the most were between 4000 and 16 000 Hz, with left ears significantly more affected than right ears. Noise levels exceeded the maximum permissible ambient noise levels in up to 43.8 per cent of low frequencies (250–1000 Hz). CONCLUSION: Mobile health supported audiometry proved to be an efficacious tool for ototoxicity monitoring at the treatment venue. Changes in hearing ability over time could be tracked, improving surveillance in patients with full treatment schedules. |
format | Online Article Text |
id | pubmed-9834705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98347052023-01-18 Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies Ehlert, K Heinze, B Graham, M A Swanepoel, D J Laryngol Otol Main Article OBJECTIVE: This study investigated mobile health enabled surveillance in ototoxicity. METHOD: This was a longitudinal study of 32 participants receiving chemotherapy. Baseline and exit audiograms that included conventional and extended high frequency audiometry were recorded within the patient's treatment venue using a validated mobile health audiometer. RESULTS: Average hearing thresholds at baseline were within the normal range (81.2 per cent left; 93.8 per cent right), reducing at exit testing (71.9 per cent left; 78.1 per cent right). Half of participants presented with a threshold shift according to ototoxicity monitoring criteria. The frequencies affected the most were between 4000 and 16 000 Hz, with left ears significantly more affected than right ears. Noise levels exceeded the maximum permissible ambient noise levels in up to 43.8 per cent of low frequencies (250–1000 Hz). CONCLUSION: Mobile health supported audiometry proved to be an efficacious tool for ototoxicity monitoring at the treatment venue. Changes in hearing ability over time could be tracked, improving surveillance in patients with full treatment schedules. Cambridge University Press 2023-01 2022-05-25 /pmc/articles/PMC9834705/ /pubmed/35611593 http://dx.doi.org/10.1017/S0022215122001281 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. |
spellingShingle | Main Article Ehlert, K Heinze, B Graham, M A Swanepoel, D Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies |
title | Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies |
title_full | Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies |
title_fullStr | Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies |
title_full_unstemmed | Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies |
title_short | Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies |
title_sort | surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies |
topic | Main Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834705/ https://www.ncbi.nlm.nih.gov/pubmed/35611593 http://dx.doi.org/10.1017/S0022215122001281 |
work_keys_str_mv | AT ehlertk surveillanceforototoxicityinplatinumbasedchemotherapyusingmobilehealthaudiometrywithextendedhighfrequencies AT heinzeb surveillanceforototoxicityinplatinumbasedchemotherapyusingmobilehealthaudiometrywithextendedhighfrequencies AT grahamma surveillanceforototoxicityinplatinumbasedchemotherapyusingmobilehealthaudiometrywithextendedhighfrequencies AT swanepoeld surveillanceforototoxicityinplatinumbasedchemotherapyusingmobilehealthaudiometrywithextendedhighfrequencies |